Panitumumab outcome by tumour location analysis
Efficacy outcomes by tumour location in patients with
WT
RAS
/WT
BRAF
disease
•
Boeckx N, et al. Ann Oncol 2016;27(Suppl 6):abstract 89P (and poster).
WT
RAS
/
WT
BRAF
PRIME
PEAK
Study 181
Pmab +
FOLFOX
FOLFOX
Pmab +
FOLFOX
Bev + FOLFOX
Pmab +
FOLFIRI
FOLFIRI
Pts, n (left/right)
156/26
148/32
52/13
53/13
143/22
144/26
Median OS, months
Left
32.5
23.6
43.4
32.0
20.1
16.9
HR (95% CI)
0.67 (0.56‒0.86)
0.77 (0.46‒1.28)
0.97 (0.76‒1.26)
Right
22.5
21.5
22.5
23.3
11.9
10.9
HR (95% CI)
0.94 (0.53‒1.67)
0.63 (0.26‒1.54)
0.84 (0.46‒1.54)
Median PFS, months
Left
12.9
9.3
14.6
11.5
8.0
6.6
HR (95% CI)
0.69 (0.54‒0.88)
0.67 (0.44‒1.02)
0.89 (0.70‒1.14)
Right
8.9
7.3
10.3
12.6
6.8
3.7
HR (95% CI)
0.71 (0.4‒1.27)
0.88 (0.39‒2.02)
0.62 (0.34‒1.13)
CR + PR, %
Left
70.3
54.8
63.5
58.5
50.7
13.5
Right
52.0
41.4
69.2
46.2
19.0
3.8
